Ligand-protein interactions of selective casein kinase 1δ inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 17, 2013, Pages 6819-6828

  Mente, Scot ^a   Arnold, Eric ^a   Butler, Todd ^a   Chakrapani, Subramanyam ^a   Chandrasekaran, Ramalakshmi ^a   Cherry, Kevin ^a   Dirico, Ken ^a   Doran, Angela ^a   Fisher, Katherine ^a   Galatsis, Paul ^a   Green, Michael ^a   Hayward, Matthew ^a   Humphrey, John ^a   Knafels, John ^a   Li, Jianke ^a   Liu, Shenping ^a   Marconi, Michael ^a   McDonald, Scott ^a   Ohren, Jeff ^a   Paradis, Vanessa ^a   Sneed, Blossom ^a   Walton, Kevin ^a   Wager, Travis ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(DIMETHYLAMINO) 1 (4 FLUOROPHENYL) 2 (PYRIDIN 4 YL)PROP 2 EN 1 ONE; 1 (4 FLUOROPHENYL) 2 (PYRIDINE 4 YL)ETHANONE; 1 [4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PYRIDINE 2 YL] N METHYLMETHANAMINE; 2 BROMO 4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PYRIDINE; 3 (4 FLUOROPHENYL) 1 METHYL 4 (4,4,5,5 TETRAMETHYL 1,3,2 DIOXABOROLAN 2 YL) 1H PYRAZOLE; 3 [4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PYRIDIN 2 YL]MORPHOLINE; 3 FLUORO 4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PICOLINONITRILE; 4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PICOLINONITRILE; 4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PYRIDINE; 4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PYRIDINE 1 OXIDE; 5 [4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PYRIDIN 2 YL] 3,6 DIHYDRO 2H 1,4 OXAZINE; [4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PYRIDIN 2 YL]METHANOL; [4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PYRIDIN 2YL]METHANAMINE; CASEIN KINASE IDELTA; CASEIN KINASE IDELTA INHIBITOR; CASEIN KINASE IEPSILON; LIGAND; METHYL 4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PICOLINATE; N [[4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PYRIDIN 2 YL]METHYL]FORMAMIDE; N [[4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PYRIDINE 2 YL]METHYL] N METHYLFORMAMIDE; PROTEIN SERINE THREONINE KINASE INHIBITOR; SYNAPTOPHYSIN; TERT BUTYL [2 [2 [4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PYRIDIN 2 YL] 2 OXOETHOXY]ETHYL]CARBAMATE; TERT BUTYL[2 [[2 CYANO 4 [3 (4 FLUOROPHENYL) 1 METHYL 1H PYRAZOL 4 YL]PYRIDIN 3 YL]OXY]ETHYL]CARBAMATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CIRCADIAN RHYTHM; DRUG DESIGN; DRUG SAFETY; ENZYME ACTIVITY; HINGE REGION; HYDROGEN BOND; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION;

CASEIN KINASE IDELTA; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEINS;

EID: 84884258244     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4006324     Document Type: Article

References (30)

1. Price, M. A. CKI, there's more than one: Casein kinase I family members in Wnt and hedgehog signaling Genes Dev. 2006, 20, 399-410
2. Gallego, M.; Virshup, D. M. Post-translational modifications regulate the ticking of the circadian clock Nat. Rev. Mol. Cell Biol. 2007, 8, 139-148
3. Knippschild, U.; Gocht, A.; Wolff, S.; Huber, N.; Löhler, J.; Stöter, M. The casein kinase 1 family: Participation in multiple cellular processes in eukaryotes Cell. Signal. 2005, 17, 675-689
4. Galatsis, P.; Wager, T. T.; Offord, J.; DeMarco, G. J.; Ohren, J. F.; Efremov, I.; Mente, S. Chapter 3-Central modulation of circadian rhythm via CK1 inhibition for psychiatric indications Annu. Rep. Med. Chem. 2011, 46, 33-51
5. Badura, L.; Swanson, T.; Adamowicz, W.; Adams, J.; Cianfrogna, J.; Fisher, K.; Holland, J.; Kleiman, R.; Nelson, F.; Reynolds, L.; St. Germain, K.; Schaeffer, E.; Tate, B.; Sprouse, J. An inhibitor of casein kinase Iε induces phase delays in circadian rhythms under free-running and entrained conditions J. Pharmacol. Exp. Ther. 2007, 322, 730-738
6. Walton, K. M.; Fisher, K.; Rubitski, D.; Marconi, M.; Meng, Q.-J.; Sladek, M.; Adams, J.; Bass, M.; Chandrasekaran, R.; Butler, T.; Griffor, M.; Rajamohan, F.; Serpa, M.; Chen, Y.; Claffey, M.; Hastings, M.; Loudon, A.; Maywood, E.; Ohren, J.; Doran, A.; Wager, T. T. Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period J. Pharmacol. Exp. Ther. 2009, 330, 430-439
7. Force, T.; Kolaja, K. L. Cardiotoxicity of kinase inhibitors: The prediction and translation of preclinical models to clinical outcomes Nat. Rev. Drug Discovery 2011, 10, 111-126
8. Kerkela, R.; Grazette, L.; Yacobi, R.; Iliescu, C.; Patten, R.; Beahm, C.; Walters, B.; Shevtsov, S.; Pesant, S.; Clubb, F. J.; Rosenzweig, A.; Salomon, R. N.; Van Etten, R. A.; Alroy, J.; Durand, J.-B.; Force, T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat. Med. 2006, 12, 908-916
9. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem. Neurosci. 2010, 1, 435-449
10. Wager, T. T.; Chandrasekaran, R. Y.; Hou, X.; Troutman, M. D.; Verhoest, P. R.; Villalobos, A.; Will, Y. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes ACS Chem. Neurosci. 2010, 1, 420-434
11. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 2006, 16, 127-136
12. Frantz, S. Drug discovery: Playing dirty Nature 2005, 437, 942-943
13. Zhang, X.; Crespo, A.; Fernández, A. Turning promiscuous kinase inhibitors into safer drugs Trends Biotechnol. 2008, 26, 295-301
14. Long, A.; Zhao, H.; Huang, X. Structural basis for the interaction between casein kinase 1 delta and a potent and selective inhibitor J. Med. Chem. 2012, 55, 956-960
15. Long, A.; Zhao, H.; Huang, X. Structural basis for the potent and selective inhibition of casein kinase 1 epsilon J. Med. Chem. 2012, 55, 10307-10311
16. Perry, J. J. P.; Harris, R. M.; Moiani, D.; Olson, A. J.; Tainer, J. A. p38α MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses J. Mol. Biol. 2009, 391, 1-11
17. Graneto, M. J.; Kurumbail, R. G.; Vazquez, M. L.; Shieh, H.-S.; Pawlitz, J. L.; Williams, J. M.; Stallings, W. C.; Geng, L.; Naraian, A. S.; Koszyk, F. J.; Stealey, M. A.; Xu, X. D.; Weier, R. M.; Hanson, G. J.; Mourey, R. J.; Compton, R. P.; Mnich, S. J.; Anderson, G. D.; Monahan, J. B.; Devraj, R. Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase J. Med. Chem. 2007, 50, 5712-5719
18. Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Structural basis for p38[alpha] MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity Nat. Struct. Mol. Biol. 2003, 10, 764-769
19. Mente, S.; Doran, A.; Wager, T. T. Getting the MAX out of computational models: The prediction of unbound-brain and unbound-plasma maximum concentrations ACS Med. Chem. Lett. 2012, 3, 515-519
20. Schmidtke, P.; Luque, F. J.; Murray, J. B.; Barril, X. Shielded hydrogen bonds as structural determinants of binding kinetics: Application in drug design J. Am. Chem. Soc. 2011, 133, 18903-18910
21. Sanguinetti, M. C.; Mitcheson, J. S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome Trends Pharmacol. Sci. 2005, 26, 119-24
22. Cavalli, A.; Poluzzi, E.; De, P. F.; Recanatini, M. Toward a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA study of HERG K+ channel blockers J. Med. Chem. 2002, 45, 3844-53
23. Aronov, A. M. Ligand structural aspects of hERG channel blockade Curr. Top. Med. Chem. 2008, 8, 1113-1127
24. Seierstad, M.; Agrafiotis, D. K. A QSAR model of hERG binding using a large, diverse, and internally consistent training set Chem. Biol. Drug Design 2006, 67, 284-296
25. Stary, A.; Wacker, S. J.; Boukharta, L.; Zachariae, U.; Karimi-Nejad, Y.; Åqvist, J.; Vriend, G.; de Groot, B. L. Toward a consensus model of the hERG potassium channel ChemMedChem 2010, 5, 455-467
26. Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal emistry of hERG optimizations: Highlights and hang-ups J. Med. Chem. 2006, 49, 5029-5046
27. Gehlhaar, D. K.; Verkhivker, G. M.; Rejto, P. A.; Sherman, C. J.; Fogel, D. B.; Fogel, L. J.; Freer, S. T. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: Conformationally flexible docking by evolutionary programming Chem. Biol. 1995, 2, 317-324
28. Anantanarayan, A.; Clare, M.; Collins, P. W.; Crich, J. Z.; Devraj, R.; Flynn, D. L.; Geng, L.; Graneto, M. J.; Hanau, C. E.; Hanson, G. J.; Hartman, S. J.; Hepperle, M.; Huang, H.; Koszyk, F. J.; Liao, S.; Metz, S.; Partis, R. A.; Perry, T. D.; Rao, S. N.; Selness, S. R.; South, M. S.; Stealey, M. A.; Talley, J. J.; Vazquez, M. L.; Weier, R. M.; Xu, X.; Khanna, I. K.; Yu, Y. United States Patent 6,525,059 B1, 2003.
29. Flotow, H.; Graves, P. R.; Wang, A. Q.; Fiol, C. J.; Roeske, R. W.; Roach, P. J. Phosphate groups as substrate determinants for casein kinase I action J. Biol. Chem. 1990, 265, 14264-14269
30. Banker, M. J.; Clark, T. H.; Williams, J. A. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding J. Pharm. Sci. 2003, 92, 967-974